KR20220147624A - 가용성 clec-2와 혈소판 수에 기초한 혈소판 활성화 측정 방법 - Google Patents

가용성 clec-2와 혈소판 수에 기초한 혈소판 활성화 측정 방법 Download PDF

Info

Publication number
KR20220147624A
KR20220147624A KR1020227032991A KR20227032991A KR20220147624A KR 20220147624 A KR20220147624 A KR 20220147624A KR 1020227032991 A KR1020227032991 A KR 1020227032991A KR 20227032991 A KR20227032991 A KR 20227032991A KR 20220147624 A KR20220147624 A KR 20220147624A
Authority
KR
South Korea
Prior art keywords
concentration
platelet
platelet count
clec
soluble
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020227032991A
Other languages
English (en)
Korean (ko)
Inventor
히로야스 이시쿠라
마사히데 가와무라
Original Assignee
가부시키가이샤 엘에스아이 메디엔스
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 가부시키가이샤 엘에스아이 메디엔스 filed Critical 가부시키가이샤 엘에스아이 메디엔스
Publication of KR20220147624A publication Critical patent/KR20220147624A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/483—Physical analysis of biological material
    • G01N33/487—Physical analysis of biological material of liquid biological material
    • G01N33/49—Blood
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H10/00—ICT specially adapted for the handling or processing of patient-related medical or healthcare data
    • G16H10/40—ICT specially adapted for the handling or processing of patient-related medical or healthcare data for data related to laboratory analysis, e.g. patient specimen analysis
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/22—Haematology
    • G01N2800/224—Haemostasis or coagulation
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medical Informatics (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Primary Health Care (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Ecology (AREA)
  • Biophysics (AREA)
  • Data Mining & Analysis (AREA)
  • Databases & Information Systems (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
KR1020227032991A 2020-02-28 2021-02-26 가용성 clec-2와 혈소판 수에 기초한 혈소판 활성화 측정 방법 Pending KR20220147624A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JPJP-P-2020-032797 2020-02-28
JP2020032797 2020-02-28
PCT/JP2021/007273 WO2021172493A1 (ja) 2020-02-28 2021-02-26 可溶型ｃｌｅｃ－２と血小板数に基づく血小板活性化測定方法

Publications (1)

Publication Number Publication Date
KR20220147624A true KR20220147624A (ko) 2022-11-03

Family

ID=77491232

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227032991A Pending KR20220147624A (ko) 2020-02-28 2021-02-26 가용성 clec-2와 혈소판 수에 기초한 혈소판 활성화 측정 방법

Country Status (6)

Country Link
US (1) US12590978B2 (https=)
EP (1) EP4113524A4 (https=)
JP (1) JP7546037B2 (https=)
KR (1) KR20220147624A (https=)
CN (1) CN115190973B (https=)
WO (1) WO2021172493A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4279606A4 (en) * 2021-01-13 2024-12-18 PHC Corporation Method for predicting risk for thrombosis in cancer patient using soluble clec2
EP4350350A4 (en) * 2021-05-31 2025-04-30 PHC Corporation METHOD FOR ASSESSING THE RISK OF HEMORRHAGIC STROKE USING SOLUBLE CLEC2
US20240264174A1 (en) * 2021-05-31 2024-08-08 Phc Corporation Method for evaluating risk of acute cerebral vascular disease using soluble clec2
WO2025075139A1 (ja) * 2023-10-06 2025-04-10 Ｐｈｃ株式会社 可溶型ｃｌｅｃ－２を用いた脳心血管・腎イベントの長期的発症ハイリスク評価法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20070070359A (ko) 2005-12-29 2007-07-04 삼성전자주식회사 액정표시장치
JP4961595B2 (ja) 2005-04-25 2012-06-27 国立大学法人山梨大学 Ｃｌｅｃ−２シグナル伝達により止血疾患を治療するための組成物および方法
JP6078845B2 (ja) 2012-09-28 2017-02-15 株式会社Ｌｓｉメディエンス 可溶型ｃｌｅｃ−２に基づく血小板活性化測定方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007070359A (ja) 2005-09-06 2007-03-22 Univ Of Yamanashi 止血疾患治療用の医薬組成物
KR101399608B1 (ko) 2007-07-27 2014-05-26 가부시키가이샤 한도오따이 에네루기 켄큐쇼 반도체 장치의 제작방법
WO2010058412A1 (en) * 2008-11-19 2010-05-27 Dilip Shrinivas Velaskar A new rapid thrombochek test kit based on whole blood screening test to detect platelet hyperaggregation at a temparature of 37°c in the clinical laboratory
US20140227265A1 (en) 2011-06-17 2014-08-14 Amgen Inc. Method of treating or ameliorating metabolic disorders using clec-2
JP6004322B2 (ja) * 2012-04-24 2016-10-05 国立大学法人 千葉大学 心血管イベントの発症リスクの検査方法
CN104285148B (zh) * 2012-05-07 2016-10-12 美迪恩斯生命科技株式会社 检测弥散性血管内凝血或感染性弥散性血管内凝血的方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4961595B2 (ja) 2005-04-25 2012-06-27 国立大学法人山梨大学 Ｃｌｅｃ−２シグナル伝達により止血疾患を治療するための組成物および方法
KR20070070359A (ko) 2005-12-29 2007-07-04 삼성전자주식회사 액정표시장치
JP6078845B2 (ja) 2012-09-28 2017-02-15 株式会社Ｌｓｉメディエンス 可溶型ｃｌｅｃ−２に基づく血小板活性化測定方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Platelets 2015; 26(8): 711-719
Thrombosis Research, 2019, Vol. 178, p. 54-58

Also Published As

Publication number Publication date
US12590978B2 (en) 2026-03-31
US20230168260A1 (en) 2023-06-01
CN115190973B (zh) 2025-10-21
EP4113524A4 (en) 2024-03-06
WO2021172493A1 (ja) 2021-09-02
JP7546037B2 (ja) 2024-09-05
CN115190973A (zh) 2022-10-14
JPWO2021172493A1 (https=) 2021-09-02
EP4113524A1 (en) 2023-01-04

Similar Documents

Publication Publication Date Title
US12590978B2 (en) Method for measuring platelet activation based on soluble CLEC-2 and platelet count
Ryu et al. Pentraxin 3: a novel and independent prognostic marker in ischemic stroke
KR102044940B1 (ko) 파종성 혈관 내 응고 증후군 또는 감염성 파종성 혈관 내 응고 증후군을 검출하는 방법
CN101460852A (zh) Mrp8/14水平用于鉴别个体处于急性冠状动脉综合症风险中的应用
Takayama et al. Dielectric blood coagulometry for the early detection of sepsis-induced disseminated intravascular coagulation: a prospective observational study
JP5847140B2 (ja) 慢性血栓塞栓性肺高血圧症の検査方法
EP4636404A2 (en) Method for evaluating risk of acute cerebral vascular disease using soluble clec2
KR20240017001A (ko) 가용형 clec2를 이용한 출혈성 뇌졸중의 리스크 평가법
HK40085757A (en) Method for measuring platelet activation based on soluble clec-2 and platelet count
JPWO2022255348A5 (https=)
Okyay et al. Turkish Society of Cardiology consensus paper on the rational use of cardiac troponins in daily practice.
KR20140023260A (ko) Cartilage Acidic Protein 1 단백질에 의한 뇌경색의 검사 방법
JP7808059B2 (ja) 可溶型ｃｌｅｃ２を用いた癌患者における血栓症リスクの予測方法
RU2789822C1 (ru) Способ оптимизации лабораторной диагностики тромбинемии у пациентов с инфекцией COVID-19
WO2025075139A1 (ja) 可溶型ｃｌｅｃ－２を用いた脳心血管・腎イベントの長期的発症ハイリスク評価法
Ateş et al. The Association Between Mean Neutrophil Volume and Dipping Status in Newly Diagnosed Hypertensive Patients
HK40127498A (en) Method for evaluating risk of acute cerebral vascular disease using soluble clec2
CA2927600C (en) Algorithm of ntprobnp and hand held ecg to detect arrhythmia in an elderly population
HK40105374A (en) Method for evaluating risk of acute cerebral vascular disease using soluble clec2
Prisco et al. D-dimer Testing and Venous Thromboembolism
JPH1123571A (ja) 糖尿病における心筋虚血の検査法

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000